Plus Therapeutics (PSTV) Competitors $0.72 -0.05 (-6.48%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. SPAI, TMDIF, DXR, APYX, BDMD, OM, TELA, MODD, FEMY, and POCIShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Safe Pro Group Inc. Common Stock (SPAI), Titan Medical (TMDIF), Daxor (DXR), Apyx Medical (APYX), Baird Medical Investment (BDMD), Outset Medical (OM), TELA Bio (TELA), Modular Medical (MODD), Femasys (FEMY), and Precision Optics (POCI). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Safe Pro Group Inc. Common Stock Titan Medical Daxor Apyx Medical Baird Medical Investment Outset Medical TELA Bio Modular Medical Femasys Precision Optics Plus Therapeutics (NASDAQ:PSTV) and Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Do institutionals and insiders believe in PSTV or SPAI? 3.3% of Plus Therapeutics shares are held by institutional investors. 5.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer PSTV or SPAI? In the previous week, Plus Therapeutics and Plus Therapeutics both had 1 articles in the media. Safe Pro Group Inc. Common Stock's average media sentiment score of 0.96 beat Plus Therapeutics' score of 0.72 indicating that Safe Pro Group Inc. Common Stock is being referred to more favorably in the news media. Company Overall Sentiment Plus Therapeutics Positive Safe Pro Group Inc. Common Stock Positive Does the MarketBeat Community prefer PSTV or SPAI? Plus Therapeutics received 72 more outperform votes than Safe Pro Group Inc. Common Stock when rated by MarketBeat users. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Safe Pro Group Inc. Common StockN/AN/A Is PSTV or SPAI more profitable? Safe Pro Group Inc. Common Stock has a net margin of 0.00% compared to Plus Therapeutics' net margin of -225.07%. Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% Safe Pro Group Inc. Common Stock N/A N/A N/A Which has higher valuation and earnings, PSTV or SPAI? Safe Pro Group Inc. Common Stock has lower revenue, but higher earnings than Plus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M2.49-$13.32M-$2.50-0.29Safe Pro Group Inc. Common Stock$2.17M22.24N/AN/AN/A Do analysts rate PSTV or SPAI? Plus Therapeutics presently has a consensus target price of $11.50, indicating a potential upside of 1,498.78%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Plus Therapeutics is more favorable than Safe Pro Group Inc. Common Stock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Safe Pro Group Inc. Common Stock 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPlus Therapeutics beats Safe Pro Group Inc. Common Stock on 7 of the 11 factors compared between the two stocks. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.23M$4.38B$5.57B$7.83BDividend YieldN/A39.98%5.11%4.21%P/E Ratio-0.2830.6722.4418.48Price / Sales2.4954.91394.10103.59Price / CashN/A51.0838.1834.62Price / Book-2.406.116.774.25Net Income-$13.32M$68.15M$3.22B$248.23M7 Day Performance-14.64%-0.12%1.48%0.89%1 Month Performance-29.48%-2.24%3.99%3.53%1 Year Performance-58.18%24.15%16.20%5.08% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics2.2339 of 5 stars$0.72-6.5%$11.50+1,498.8%-58.7%$12.23M$4.91M-0.2820Gap DownSPAISafe Pro Group Inc. Common StockN/A$2.70+9.8%N/AN/A$40.96M$2.17M0.0011Gap UpTMDIFTitan MedicalN/A$0.36+7.8%N/A+554.9%$40.77M$17.63M-0.2950Gap UpDXRDaxor3.9917 of 5 stars$7.98+7.7%$25.00+213.3%-23.8%$38.60M$2.13M0.0037Gap UpAPYXApyx Medical1.374 of 5 stars$0.98+0.5%N/A-27.3%$37.04M$48.10M-1.18270Upcoming EarningsShort Interest ↑Gap DownBDMDBaird Medical InvestmentN/A$5.55-0.7%N/AN/A$36.54M$33.05M0.00N/AGap DownOMOutset Medical0.9482 of 5 stars$9.98-9.4%$35.00+250.7%-72.0%$35.88M$113.69M-4.02520Upcoming EarningsTELATELA Bio2.9759 of 5 stars$0.89-6.9%$7.25+714.6%-78.5%$35.06M$69.30M-0.53120Upcoming EarningsShort Interest ↓Positive NewsGap UpMODDModular Medical1.9571 of 5 stars$0.85-4.2%N/A-31.6%$34.61MN/A-1.6120Short Interest ↓Negative NewsFEMYFemasys3.4067 of 5 stars$1.20-3.2%$11.50+858.3%-8.7%$32.58M$1.63M-1.4830Upcoming EarningsShort Interest ↓Positive NewsPOCIPrecision Optics0.6269 of 5 stars$3.99+1.0%N/A-20.7%$30.59M$18.68M-6.2380Positive NewsGap Up Related Companies and Tools Related Companies Safe Pro Group Inc. Common Stock Competitors Titan Medical Competitors Daxor Competitors Apyx Medical Competitors Baird Medical Investment Competitors Outset Medical Competitors TELA Bio Competitors Modular Medical Competitors Femasys Competitors Precision Optics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
